BD Opens Advance Diabetes Care Headquarters in Andover, Mass.
BD expands its Massachusetts footprint with “Center of Excellence” to develop next generation technology for diabetes treatment
Jun 15, 2015
ANDOVER, MA, July 15, 2015 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, officially opened its Advanced Diabetes Care facility in Andover, Mass., which will house research and development (R&D) and manufacturing of novel solutions for Type 1 and Type 2 diabetes.
“The opening of this facility represents an exciting opportunity for BD to accelerate the development of next-generation technologies to help simplify the management of Type 1 and Type 2 diabetes,” said Dr. Ellen Strahlman, chief medical officer and executive vice president of Research & Development at BD. “This new model will help increase the rate of innovation and enable us to provide therapeutic advances in the diabetes care sector.”
The Andover facility, which will serve as the new headquarters for BD’s Advanced Diabetes Care platform, incorporates a “Center of Excellence” model, bringing R&D and manufacturing of solutions for Type 1 and Type 2 diabetes patients under one roof. The joining of multiple disciplines in one, central location allows for improved synergies in diabetes advancements. Approximately 100 associates will be located in the 75,000 square foot facility.
BD would like to recognize and thank the Massachusetts government officials and representatives of local organizations who participated in the ceremonial ribbon cutting.
Given its proximity to Nepal, AmeriCares India served a critical role to bring supplies, relief workers (including medical personnel and logistics experts) to Nepal and coordinate aid delivery. The agency mounted one of its most significant disaster management efforts and collaborated closely with BD India to provide emergency medical and primary care, ensure access to critical medicines and supplies and re-establish health services in impacted areas.
(L-R): Massachusetts Office of Business Development Senior Regional Director Peter Milano; Mass. State Senator Barbara L’Italian; Massachusetts Life Sciences Center Vice President Pamela Norton; BD Vice President Global Operations Jim Borzi; Mass. Assistant Secretary of Business Development Nam Pham; BD Executive Vice President R&D and Chief Medical Officer Dr. Ellen Strahlman; Town of Andover Director of Planning Paul Materazzo; BD Medical – Diabetes Care Worldwide President Ken Miller. (Photo: Courtesy of BD)
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
For more information on BD, please visit bd.com.
About Cellular Research, Inc.
Cellular Research, Inc. is a biotechnology research and development company founded by innovators from Silicon Valley and Stanford University. Our mission is to develop and commercialize a new generation of highly sensitive life science technologies and products. In addition to introducing a portfolio of research products, the Company has an active partnership program with pharmaceutical and diagnostics companies advancing clinical applications. For more information, please visit http://www.cellular-research.com/ and follow us on Twitter @Cell_Research.
Monique N. Dolecki
201 847 5378
Back to News Releases